720 related articles for article (PubMed ID: 18465328)
1. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
2. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
5. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
7. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
[TBL] [Abstract][Full Text] [Related]
8. The role of TP53 in breast cancer development.
Eeles RA; Bartkova J; Lane DP; Bartek J
Cancer Surv; 1993; 18():57-75. PubMed ID: 8013000
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
10. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
12. [Peripheral blood mutated p53 DNA and its clinical value in human breast cancer].
Di GH; Liu G; Wu J; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2003 Mar; 25(2):137-40. PubMed ID: 12795838
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
16. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
Hosny G; Farahat N; Hainaut P
Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
[TBL] [Abstract][Full Text] [Related]
20. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]